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Objective. To analyze the potential role of colchicine monotherapy in patients with tumor necrosis factor receptor associated
periodic syndrome (TRAPS) in terms of control of clinical and laboratory manifestations. Methods. Patients with TRAPS treated
with colchicine monotherapy were retrospectively enrolled; demographic, clinical and therapeutic data were collected and
statistically analysed after having clustered patients according to different times at disease onset, penetrance of mutations,
dosage of colchicine, and different disease manifestations. Results. 24 patients (14 males; 15 with pediatric disease onset) treated
with colchicine monotherapy were enrolled. Colchicine resulted in a complete response in 3 (12.5%) cases, partial response in 14
(58.3%) patients, and lack of response in 7 (29.2%) patients. There were not significant differences in colchicine response
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between pediatric and adult disease onset (p = 0:42), between low- and high-penetrance mutations (p = 0:62), and according to
different dosages (p = 0:66). No significant differences were identified in the frequency of specific disease manifestations between
patients experiencing any response to colchicine and patients with lack of response. Conclusions. Colchicine monotherapy is
useful in a low percentage of TRAPS patients; nevertheless, it could be attempted in patients with milder phenotypes and at a
lower risk of developing reactive amyloidosis.
1. Introduction
Tumor necrosis factor receptor associated periodic syndrome
(TRAPS) is an autoinflammatory autosomal dominant
disease caused by mutations in the TNFRSF1A gene and is
characterized by typically prolonged recurrent fever attacks.
Erythematous skin rash, ocular and periocular manifesta-
tions, joint involvement, andmyalgia sustained by monocytic
fasciitis are additional and frequent symptoms observed
during flares [1]. TRAPS is characterized by a protean
spectrum of clinical features and severity depending on
specific gene mutations: high-penetrance mutations gener-
ally manifest with an early onset, along with severe and
typical manifestations; conversely, low-penetrance mutations
are more frequently identified in adult-onset patients and
often lead to less severe or atypical disease features with a
very low risk for amyloidosis [2–4].
Nowadays, therapy with interleukin- (IL-) 1 inhibitors is
considered the standard of therapy with the highest ratio
between clinical efficacy and safety profile [5, 6]. On the other
hand, colchicine, which represents the gold standard treat-
ment in patients with familial Mediterranean fever (FMF)
for controlling clinical manifestations and reactive amyloid-
osis [7], is generally considered useless for the management
of TRAPS patients [8]. Nevertheless, cases at least partially
responsive to colchicine have also been described [8–10].
For this reason, we have conducted the present study to
better investigate the role of colchicine as possible treatment
option in TRAPS.
2. Methods
TRAPS patients treated with colchicine monotherapy were
retrospectively enrolled in eleven Italian referral Centres.
Diagnosis of TRAPS was based on suggestive clinical
manifestations and supported by genetic analysis (Sanger
sequencing of TNFRSF1A gene driven by clinical features or
next-generation sequencing). In order to definitively exclude
patients that could possibly benefit from colchicine adminis-
tration for any other concomitant diseases, subjects fulfilling
clinical diagnostic and classification criteria for Behçet’s dis-
ease and periodic fever, aphthous stomatitis, pharyngitis and
cervical adenitis (PFAPA) syndrome were ruled out [11–14].
The primary aim of the study was to assess clinical bene-
fits of colchicine in TRAPS patients distinguishing cases
according to different times at disease onset (pediatric- vs
adult-onset TRAPS) and penetrance of mutations (high- vs
low-penetrance). Secondary aims of the study were (i) to
identify any difference in colchicine response on the bases
of different clinical manifestations and different colchicine
dosage employed and (ii) to search for any differences in
colchicine role according to the response of TRAPS patients
to corticosteroids, nonsteroidal anti-inflammatory drugs
(NSAIDs), and biologics.
Complete response was defined as complete control of
clinical and laboratory manifestations; partial response was
meant as (i) a decrease in clinical severity of disease attacks
after colchicine introduction testified by a mean reduction
of body temperature ≥ 1°C during flares and a ≥30% decrease
of erythrocyte sedimentation rate (ESR), C reactive protein
(CRP), and serum amyloid A (SAA) assessed during inflam-
matory episodes, and (ii) a patient-reported improvement in
clinical manifestations during flares for relapsing-remitting
disease courses or outside of flares for chronic cases. Because
of the small sample size, patients experiencing complete
response and partial response were grouped together in order
to compare patients presenting any colchicine response with
patients undergoing failure.
Descriptive statistics was based on the evaluation of
mean, standard deviation (SD), and median and interquartile
range (IQR) values. For qualitative data, pairwise compari-
sons were performed using 2 × 2 and 2 × 3 contingency tables
and applying the Fisher exact test and Freeman-Halton exten-
sion when required; Student t-test or Mann–Whitney U test,
as needed, were used for pairwise comparisons of quantitative
data. Normality distribution was assessed using the Shapiro-
Wilk test. Correlations were performed employing Kendall’s
tau-b test. The SPSS software, version 24, was used for all sta-
tistical computations, always considering a significance level of
95% (p value < 0.05); all tests performed were two-sided.
The study has been approved by the local Ethics Com-
mittee of Azienda Ospedaliera Universitaria Senese, Siena,
Italy (AIDA Project; Ref. N. 14951). The study protocol
conformed to the tenets of the Declaration of Helsinki;
informed consent was obtained from all patients enrolled
or their legal guardians.
3. Results
Twenty-four TRAPS patients (14males; 15 with pediatric dis-
ease onset) treatedwith colchicine during their clinical history
were retrospectively enrolled. Their demographic and clinical
data are summarized in Table 1. High-penetrance mutations
identified in our cohort were C98Y (n = 2), C52Y (n = 1),
T50M (n = 1), Y103_R104DEL (n = 1), and c.472+1G>A
(n = 1). Low-penetrance mutations detected in the patients
enrolled were R92Q (n = 14), D12E (n = 1), P46L (n = 1),
R104Q (n = 1), and V95M (n = 1).
Colchicine resulted in a complete response in 3 (12.5%)
cases, partial response in 14 (58.3%) patients, and lack of
response in 7 (29.2%) patients.
Figure 1 shows the frequency of response to colchicine
according to TRAPS age at onset. No statistically significant
differences were highlighted between pediatric and adult
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disease onset in colchicine response (p = 0:42). Similarly, no
significant difference was identified in colchicine response
between patients treated with 1mg/day and those treated
with more than 1mg/day (p = 0:66), as shown in Figure 2.
No significant differences were identified between low-
and high-penetrance mutations according to the response
to colchicine (p = 0:62). No differences were identified in
the frequency of TRAPS-related clinical manifestations
between patients’ responsive and not responsive to colchi-
cine, as summarized in Table 2.
Two out of three patients experiencing complete disease
control did not necessitate biologic treatment; however, one
patient was later treated with the IL-1β antagonist canakinu-
mab because of gastrointestinal intolerance to colchicine.
Ten out of 14 patients experiencing partial efficacy
were later treated with anti-IL-1 biologic agents in order
to obtain complete TRAPS control; conversely, 4 patients
were treated by combining colchicine with low-dose corti-
costeroids or NSAIDs.
Figure 3 describes colchicine response according to the
final response to biologic agents (anakinra in 9 cases, canaki-
numab in 4 cases, and etanercept in 1 case), NSAIDs, and
corticosteroids. No differences were observed in the response
to corticosteroids (p = 1:00), NSAIDs (p = 0:19), and biologic
agents (p = 0:32) on the basis of different types of response to
colchicine (failure versus complete and partial response). No
significant correlation was identified between colchicine
response and response to NSAIDs (p = 0:10), corticosteroids
(p = 1:00), or biologics (p = 0:15).
Regarding laboratory inflammatory markers, acute phase
reactants normalized in patients showing complete response
to colchicine, while patients experiencing partial response
showed a ≥30% decrease of ESR, CRP, and SAA values
during attacks. However, ESR and SAA assessed during flares
Table 1: Demographic and clinical features of patients enrolled.
Demographic and clinical information
Age at disease onset in years, mean (SD) 16:4 ± 13:1
Age at diagnosis in years, mean (SD) 30:0 ± 14:1
Age at enrollment in years, mean (SD) 35:3 ± 18:8
Male/female patients 10/14
Patients with pediatric onset-TRAPS, n (%) 13 (54.2)
Patients with adult onset-TRAPS, n (%) 11 (45.8)
High-/low-penetrance mutations 6/18
Family members with symptoms, n (%) 10 (41.7)
Relapsing-remitting disease course, n (%) 18 (75)
Chronic disease course, n (%) 6 (25)
Duration of flares 10.8± 7.9
Flares/year 2.43± 0.8
Amyloidosis at diagnosis 1 (4.2)
Clinical manifestations during flares, n (%)
Thoracic pain 10 (41.7)
Pericarditis 9 (37.5)
Pleuritis 2 (8.3)
Abdominal pain 13 (54.2)
Pharyngitis 9 (37.5)
Oral aphthosis 6 (25)





Periorbital pain 4 (16.7)
Laboratory findings
Median erythrocyte sedimentation rate,
mm/1 h (IQR)
55.7 (42)
Median C-reactive protein, mg/L (IQR) 7.7 (10.5)
Median serum amyloid A, mg/L (IQR) 59.7 (63)
Proteinuria, n (%) 1 (4.2)
Abbreviations: IQR: interquartile range; n: number of patients; SD: standard














Figure 1: Response to colchicine treatment distinguishing patients











Complete response Partial response Failure 
Dosage: 1 mg/day
Dosage: > 1 mg/day
p = 0.66
Figure 2: Response to colchicine administration according to
different dosages employed (1mg/day versus more than 1mg/day).
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remained above normal values in 6/14 (42.9%) patients
partially responsive to colchicine, while CRP persisted ele-
vated in 8/14 (57.1%) patients.
4. Discussion
Colchicine is considered the treatment of choice in FMF
patients and is used as prophylactic therapy for secondary
amyloidosis in such cases [7, 15]. Indeed, colchicine has been
shown to reduce the frequency of FMF attacks and prevent
development of proteinuria related to amyloidosis [7]. Note-
worthy, it may induce improvement of proteinuria even in
patients with established amyloid nephropathy [16]. On the
contrary, colchicine is commonly considered ineffective for
treating patients with TRAPS, but studies specifically asses-
sing the role of colchicine in these patients are controversial.
In particular, during the early 2000s Dodé et al. and Drewe
et al. reported an overall lack of response to colchicine in
patients with different TNFRSF1A mutations [17, 18].
Conversely, basing on 25 patients treated with colchicine,
Ravet et al. reported complete response in 6 cases, partial
efficacy in 9 cases, and inefficacy in 10 patients [10]. Simi-
larly, the retrospective analysis of data from the Eurofever
Registry reported a beneficial effect of colchicine in 21/39
TRAPS patients, especially subjects carrying the low-
penetrance R92Q mutation [8].
The results of the present study confirm the poor role of
colchicine monotherapy for the management of TRAPS
patients. Indeed, only three cases showed a complete response
to this treatment when used before starting biologics, which
currently represent the standard of treatment in such patients.
Nevertheless, about half of patients enrolled in the study expe-
rienced a partial response in terms of control of clinical man-
ifestations and decrease of systemic inflammation during
Table 2: Demographic and clinical manifestations of patients distinguished on the basis of response to colchicine (complete and partial




(n = 7) p value
Demographic and clinical information
Age at disease onset in years, mean (IQR) 16.7 (20) 8.2 (9.8) 0.31
Age at diagnosis in years, mean (SD) 33:9 ± 15:4 22:5 ± 10:1 0.21
Male/female patients 3/4 7/10 1.00
Patients with pediatric onset-TRAPS, n (%) 8 (47.1) 5 (71.4)
0.39
Patients with adult onset-TRAPS, n (%) 9 (52.9) 2 (28.6)
High-/low-penetrance mutations (%/%) 5/12 (83.3/66.7) 1/6 (16.7/33.3) 0.62
Family members with symptoms, n (%) 7 (41.2) 3 (42.9) 1.00
Relapsing-remitting disease course, n (%) 13 (76.5) 5 (71.4)
1.00
Chronic disease course, n (%) 4 (23.5) 2 (28.6)
Duration of flares, (IQR) 10.1 (8) 12.33 (18) 0.90
Flares/year, (IQR) 2.29 (1) 3.00 (2) 0.22
Amyloidosis at diagnosis 1 (5.9) 0 (0) 0.54
Clinical manifestations during flares, n (%)
Thoracic pain 7 (41.2) 3 (42.9) 1.00
Pericarditis 7 (41.2) 2 (28.6) 0.67
Pleuritis 2 (11.8) 0 (0) 1.00
Abdominal pain 8 (47.1) 5 (71.4) 0.39
Pharyngitis 7 (41.2) 2 (28.6) 0.67
Oral aphthosis 3 (17.6) 3 (42.9) 0.31
Skin rash 7 (41.2) 2 (28.6) 0.78
Lymphadenopathy 5 (29.4) 3 (42.9) 0.65
Myalgia 10 (58.8) 5 (71.4) 0.67
Arthralgia 12 (70.6) 5 (71.4) 1.00
Arthritis 3 (17.6) 2 (28.6) 0.61
Periorbital pain 2 (11.8) 2 (28.6) 0.55
Laboratory findings
Median erythrocyte sedimentation rate, mm/1 h (IQR) 63.3 (51) 31 (37) 0.08
Median C-reactive protein, mg/L (IQR) 8.0 (7.9) 7.1 (10.7) 0.89
Median serum amyloid A, mg/L (IQR) 60.2 (69.4) 59.4 (89.2) 0.37
Proteinuria, n (%) 1 (5.9) 0 (0) 0.48
Abbreviations: IQR: interquartile range; n: number of patients; SD: standard deviation; TRAPS: tumor necrosis factor associated periodic syndrome.
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flares. These results were influenced by neither the age at
disease onset nor the different penetrance of mutations
included in the study. In regard to this last issue, controversial
results have been reported in the literature. Our findings are
consistent with what is described by Ravet et al., who reported
no definite difference in the efficacy of colchicine between
different groups of mutations [10]. Differently, other authors
have found a better response to colchicine in patients carrying
low-penetrance mutation R92Q [8]. Although no statistical
significances were observed, in our study, the percentage of
patients benefiting from colchicine administration was even
higher among patients carrying high-penetrance mutations.
These discrepancies may be related to the low number of
patients enrolled along with the different methodologies,
especially concerning the definition of partial response. For
these reasons, this matter should be further addressed in
future studies conducted on a wider number of patients to
better clarify whether colchicine response may be part of a
genotype-phenotype correlation.
Of note, as illustrated in Figure 2, patients treated with a
higher than 1mg/day dose of colchicine did not experience a
better clinical response compared to patients administered
with 1mg/day, thus suggesting no significant improvement
in clinical response by increasing colchicine dosage.
No specific clinical manifestations showed to be signifi-
cantly more frequent among patients with any response to
colchicine compared with those showing absence of efficacy.
This suggests the lack of a specific subset of TRAPS patients
identifiable as more responsive to colchicine.
As shown in Figure 3, particularly worth considering
is that colchicine response did not correlate with response
to other treatment approaches. Consequently, response to
colchicine appears independent of response to other
therapies.
The limitations of this study include its retrospective
nature and the small sample size of patients. In addition,
our study does assess neither the role of colchicine com-
bined with NSAIDs, corticosteroids, and biologic agents
nor the trend of inflammatory markers outside of disease
flares, which is a primary issue in the management of
autoinflammatory diseases, as persistently high acute phase
reactants may be linked to long-term complications
including secondary amyloidosis. However, in spite of
these limitations, at the best of our knowledge, this study
represents the first attempt at primarily assessing the role
of colchicine in TRAPS patients according to different
clinical features.
In conclusion, evidences drawn from our study suggest
that colchicine monotherapy may adequately control TRAPS
manifestations only in a few cases; however, it may represent
a feasible attempt to minimize immunosuppressive therapy
in selected TRAPS patients with milder phenotypes and at a
lower risk of developing reactive amyloidosis.
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Figure 3: Response to colchicine administration distinguishing patients according to the final response to nonsteroidal anti-inflammatory
drugs (NSAIDs), corticosteroids (CS), and biologic agents. In order to facilitate the reading of the histograms, patients experiencing
complete response and partial response were meshed to be compared with patients presenting colchicine failure.
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